Larimar Therapeutics (LRMR) Other financing activities (2014 - 2020)

Larimar Therapeutics (LRMR) has reported Other financing activities for 7 consecutive years, with $8.4 million the latest figure, recorded in Q2 2020.

• For the quarter ending Q2 2020, Other financing activities rose 180.94% year-over-year to $8.4 million; the trailing twelve-month figure through Dec 2020 stood at $18.0 million (changed N/A YoY), and the FY2020 full-year result was $18.0 million, down 7.22% from the prior year.
• Other financing activities eased to $8.4 million in Q2 2020 per LRMR's latest filing, from $9.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $64.2 million in Q3 2018 and bottomed at -$62.2 million in Q4 2018.
• Historically, Other financing activities has averaged $2.8 million across 5 years, with a median of $261000.0 in 2018.
• The sharpest annual moves came in 2018 and 2019: Other financing activities surged 80166.25% in 2018, then plunged 84.51% in 2019.
• Over 5 years, Other financing activities stood at $165000.0 in 2016, then sank by 51.52% to $80000.0 in 2017, then sank by 77850.0% to -$62.2 million in 2018, then surged by 116.0% to $9.9 million in 2019, then declined by 15.57% to $8.4 million in 2020.
• According to Business Quant data, Other financing activities over the past three periods registered $8.4 million, $9.6 million, and $9.9 million for Q2 2020, Q1 2020, and Q3 2019 respectively.